A61K 40/48
Allergens
A61K40/48 (Allergens) appears on 39 US grants and 88 published applications in this corpus.
Search patents in A61K- Granted patents
- 39
- Published applications
- 88
- Assignees
- 54
- Inventors
- 127
- Latest grant
- 28 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 1 |
| 2002 | 1 | 1 |
| 2003 | 0 | 3 |
| 2004 | 0 | 4 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 3 |
| 2008 | 0 | 1 |
| 2009 | 0 | 2 |
| 2010 | 2 | 6 |
| 2011 | 3 | 9 |
| 2012 | 5 | 3 |
| 2013 | 3 | 16 |
| 2014 | 2 | 3 |
| 2015 | 0 | 1 |
| 2016 | 3 | 2 |
| 2017 | 1 | 1 |
| 2018 | 2 | 5 |
| 2019 | 1 | 3 |
| 2020 | 3 | 3 |
| 2021 | 3 | 5 |
| 2022 | 1 | 5 |
| 2023 | 3 | 4 |
| 2024 | 1 | 3 |
| 2025 | 1 | 2 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Engineered immune cells to target SARS-CoV228 Jul 2026US 12,691,146 B2The Johns Hopkins University
- Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases23 Sep 2025US 12,421,293 B2Jura Bio, Inc.
- Anti-allergic peptide and use thereof for immune regulation and anti-allergy31 Dec 2024US 12,180,306 B2Greenyn Biotechnology Co., Ltd
- Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases28 Nov 2023US 11,826,385 B2Jura Bio, Inc.
- Method for producing myeloid-derived suppressor cells, myeloid-derived suppressor cells produced thereby, and methods thereof7 Nov 2023US 11,806,364 B2Industry-Academic Cooperation Foundation, Yonsei University
- Engineered immune cells to target sars-cov228 Aug 2025US 2025/0268937 A1The Johns Hopkins University
- Anti-allergic peptide and use thereof for immune regulation and anti-allergy6 Mar 2025US 2025/0074940 A1Greenyn Biotechnology Co., Ltd
- Major histocompatibility complex-based chimeric receptors and uses thereof for treating autoimmune diseases23 May 2024US 2024/0165158 A1Jura Bio, Inc.
- Immunogenic peptides and their use in immune disorders1 Feb 2024US 2024/0034759 A1Imcyse SA
- Novel aminoalkyl glucosaminide 4-phosphate derivative4 Jan 2024US 2024/0002425 A1Daiichi Sankyo Company, Limited
Most cited
By later US patents
- Non-specific immune system enhancement24US 5,147,289 ATherakos, Inc. · 1992
- Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease22US 7,842,501 B2Ortho-McNeil Pharmaceutical, Inc. · 2010
- Specific immune system modulation16US 5,651,993 AYale University · 1997
- Immunogenic peptides and their use in immune disorders15US 9,249,202 B2Katholieke Universiteit Leuven, K. U. Leuven R&D · 2016
- Therapeutical composition containing dentritic cells and use thereof11US 8,415,152 B2Helmholtz-Zentrum FüR Infektionsforschung GmbH · 2013